MYNZ
Mainz Biomed N.V.
stock NASDAQ

MYNZ isn’t just a concept anymore

The biotech IPO market is finally starting to wake up (look at Aktis Oncology recently). When the big players start moving, it’s usually a signal that money is about to flow back into smaller, high-potential companies.
For micro-cap diagnostic firms, this is the "make or break" moment. They either get crushed by bad debt or they find smart ways to fund their growth.
I’ve been watching Mainz Biomed (MYNZ) lately because they seem to be playing the long game very well. While everyone is chasing hype, they are actually building a real business:
* Europe is Live: They aren't just "planning" to sell; they already have a product on the market in Germany and just launched in Switzerland and the UK.
* Big Name Partners: They are working with Thermo Fisher on tech and have Quest Diagnostics lined up for the U.S. market once they get through their clinical trials.
* The "Secret" Weapon: They aren't just doing colon cancer; they are working on a pancreatic cancer blood test that just got government funding in Germany. That’s basically "free" money that doesn't hurt shareholders.
The company is heading toward a huge data update (top-line results) in Q4 2025. If the numbers look good, the path to the U.S. market becomes very real.
What do you think is the biggest catalyst here? Is it the actual sales numbers coming out of Europe, or the upcoming trial data for the U.S. FDA path? If the market stays hot into 2026, this looks like a classic "execution" story.
Not financial advice. Just sharing what I’m seeing on the charts and news wires.

The "biotech winter" seems to be ending. With new companies like Aktis Oncology filing for IPOs, investors are finally willing to take risks again. For small diagnostic companies, this is a huge deal because it means they can raise money on much better terms instead of hurting their early shareholders.
This is exactly why Mainz Biomed (MYNZ) is on my radar right now. While the market was quiet, they were actually busy building:
* Real Sales in Europe: They just launched their colon cancer test (ColoAlert) in Switzerland this September and got the green light in the UK. They aren't just a "concept" anymore-they have a product on the market.
* The Big U.S. Goal: The eAArly DETECT 2 study is presently underway. We’re expecting top-line results in Q4 2025. This is the final step before they start their big U.S. "pivotal" study in 2026.
* Strong Partners: They are working with giants like Thermo Fisher on tech and have Quest Diagnostics lined up for the U.S. market.
* Extra Projects: They even secured government funding (ISB bank) for a new pancreatic cancer blood test, which means they aren't spending all their own cash on R&D.
The company's shares have recently met all listing requirements once again and maintained a stable price point of 1.35, consistent with the previous financing stage. If the IPO window stays open and they drop strong data from their German sales or the U.S. study this quarter, the math for 2026 looks very different.
Which element do you consider the most pivotal for future growth?
1. The Q4 clinical data?
2. Sales numbers from the new UK and Swiss launches?
3. More "free" government money for their pipeline?
Not financial advice. Just following the charts and the news.

The market just got a massive wake-up call. When giants like Abbott acquire leaders like Exact Sciences, they are sending a clear message: early cancer detection is the future of healthcare. It’s no longer just a "nice to have" technology; it’s a strategic goldmine.
When the big guys start buying, smart investors look at the smaller platforms that are already proven and scaling. That’s why Mainz Biomed (MYNZ) is currently on my radar.
They aren't just a "concept" company-their product, ColoAlert, is already being sold and used across Europe. They have a smart business model: they sell the kits to partner labs who do the heavy lifting. This means they can grow fast without spending a fortune on new buildings or equipment.
A few reasons why the tech looks solid:
* High Accuracy: Their next-gen tests are showing incredible numbers-around 92% sensitivity for colorectal cancer and over 95% for high-grade dysplasia.
* Real Distribution: They just boosted their reach in Germany through DoctorBox and are expanding into the UK and Switzerland.
* Low Overhead: By using partner labs, they keep costs down while increasing volume.
What I’m watching for next: I want to see the actual sales numbers from their new European partners and, more importantly, a firm date for their U.S. clinical trials. If they can bring this tech to the American market, the current "small-cap" valuation might not last long.
Is anyone else tracking the shift from treatment to early detection? It feels like the next big wave in biotech.

Pancreatic cancer kills fast. Annual deaths are \~466,000 globally with a fatality rate near 93 percent. Early detection is rare, which is why a credible screen would be a big deal. MYNZ reported feasibility for PancAlert with 100 percent sensitivity and 95 percent specificity in early testing. It is early stage, but it uses the same mRNA plus analytics playbook the company applies in CRC.
CRC remains the core. ColoAlert is already used in Europe, now inside DoctorBox in Germany, and pooled next gen accuracy is quotable at \~92 percent CRC sensitivity, \~82 percent advanced adenomas, and \~95.8 percent high grade dysplasia. If the pancreas program advances with a blinded validation plan, a funded study timeline, and reuse of the ColoAlert workflow, the platform story gains real weight without heavy capex.
Do Your Own DD.

In shaky markets, recurring healthcare spend tends to hold. Preventive cancer screening is one of those lines. Colorectal cancer is roughly 1.9 million new cases and about 935,000 deaths per year worldwide. Five-year survival is near 90 percent when localized, but around 13 percent when distant. That math is why payers keep funding early detection even when risk assets wobble.
For MYNZ, the Europe-first story is tangible. ColoAlert is marketed via partner labs and now sits inside DoctorBox in Germany, an app with 1,000,000 plus registered users and 10M plus test results. Germany alone sees roughly 60,000 new CRC cases each year. Clinically, pooled next-gen performance is quotable: about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high-grade dysplasia. The decentralized kit model lets new labs come online without heavy capex.
Eyeing this sector, names like this can re-rate fast.

Colorectal cancer is huge and urgent. Roughly 1.9 million new cases and about 935,000 deaths worldwide each year. In the U.S., five year survival is near 90 percent when localized and about 13 percent when distant. Germany alone sees around 60,000 new cases per year. Early detection moves patients from late therapy to quick intervention.
For MYNZ, a single clean update can shift the multiple if it includes hard adoption data plus accuracy. ColoAlert’s pooled next gen read is roughly 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. Pair that with DoctorBox conversion, completed kits per week, median turnaround, and early reorders in Germany. Add a dated U.S. feasibility read and the path to a pivotal moves from talk to timeline.
If those metrics land together, investors can model real volume instead of headlines. If they do not, it remains a trading vehicle.
Do your own DD too

Big buyers just told the market where growth sits: cancer screening and precision diagnostics. Abbott agreeing to acquire Exact Sciences is not about one brand. It is a statement that early detection is strategic, scalable, and worth paying up for. If that is true for the giants, it sets a supportive backdrop for smaller platforms that already have product in use.
That is why I keep MYNZ on screen. ColoAlert is live in Europe through partner labs, with German distribution now boosted by DoctorBox. Clinically, pooled next gen reads are strong: roughly 92% CRC sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia. The business model is kits plus partner labs, so volume can scale without heavy capex. What I want next: DoctorBox conversion and completions, early reorders by region, and a firm U.S. feasibility date that moves the FDA path from talk to timeline.

MYNZ isn’t just a concept anymore

The biotech IPO market is finally starting to wake up (look at Aktis Oncology recently). When the big players start moving, it’s usually a signal that money is about to flow back into smaller, high-potential companies.
For micro-cap diagnostic firms, this is the "make or break" moment. They either get crushed by bad debt or they find smart ways to fund their growth.
I’ve been watching Mainz Biomed (MYNZ) lately because they seem to be playing the long game very well. While everyone is chasing hype, they are actually building a real business:
* Europe is Live: They aren't just "planning" to sell; they already have a product on the market in Germany and just launched in Switzerland and the UK.
* Big Name Partners: They are working with Thermo Fisher on tech and have Quest Diagnostics lined up for the U.S. market once they get through their clinical trials.
* The "Secret" Weapon: They aren't just doing colon cancer; they are working on a pancreatic cancer blood test that just got government funding in Germany. That’s basically "free" money that doesn't hurt shareholders.
The company is heading toward a huge data update (top-line results) in Q4 2025. If the numbers look good, the path to the U.S. market becomes very real.
What do you think is the biggest catalyst here? Is it the actual sales numbers coming out of Europe, or the upcoming trial data for the U.S. FDA path? If the market stays hot into 2026, this looks like a classic "execution" story.
Not financial advice. Just sharing what I’m seeing on the charts and news wires.

The "biotech winter" seems to be ending. With new companies like Aktis Oncology filing for IPOs, investors are finally willing to take risks again. For small diagnostic companies, this is a huge deal because it means they can raise money on much better terms instead of hurting their early shareholders.
This is exactly why Mainz Biomed (MYNZ) is on my radar right now. While the market was quiet, they were actually busy building:
* Real Sales in Europe: They just launched their colon cancer test (ColoAlert) in Switzerland this September and got the green light in the UK. They aren't just a "concept" anymore-they have a product on the market.
* The Big U.S. Goal: The eAArly DETECT 2 study is presently underway. We’re expecting top-line results in Q4 2025. This is the final step before they start their big U.S. "pivotal" study in 2026.
* Strong Partners: They are working with giants like Thermo Fisher on tech and have Quest Diagnostics lined up for the U.S. market.
* Extra Projects: They even secured government funding (ISB bank) for a new pancreatic cancer blood test, which means they aren't spending all their own cash on R&D.
The company's shares have recently met all listing requirements once again and maintained a stable price point of 1.35, consistent with the previous financing stage. If the IPO window stays open and they drop strong data from their German sales or the U.S. study this quarter, the math for 2026 looks very different.
Which element do you consider the most pivotal for future growth?
1. The Q4 clinical data?
2. Sales numbers from the new UK and Swiss launches?
3. More "free" government money for their pipeline?
Not financial advice. Just following the charts and the news.

The market just got a massive wake-up call. When giants like Abbott acquire leaders like Exact Sciences, they are sending a clear message: early cancer detection is the future of healthcare. It’s no longer just a "nice to have" technology; it’s a strategic goldmine.
When the big guys start buying, smart investors look at the smaller platforms that are already proven and scaling. That’s why Mainz Biomed (MYNZ) is currently on my radar.
They aren't just a "concept" company-their product, ColoAlert, is already being sold and used across Europe. They have a smart business model: they sell the kits to partner labs who do the heavy lifting. This means they can grow fast without spending a fortune on new buildings or equipment.
A few reasons why the tech looks solid:
* High Accuracy: Their next-gen tests are showing incredible numbers-around 92% sensitivity for colorectal cancer and over 95% for high-grade dysplasia.
* Real Distribution: They just boosted their reach in Germany through DoctorBox and are expanding into the UK and Switzerland.
* Low Overhead: By using partner labs, they keep costs down while increasing volume.
What I’m watching for next: I want to see the actual sales numbers from their new European partners and, more importantly, a firm date for their U.S. clinical trials. If they can bring this tech to the American market, the current "small-cap" valuation might not last long.
Is anyone else tracking the shift from treatment to early detection? It feels like the next big wave in biotech.

Pancreatic cancer kills fast. Annual deaths are \~466,000 globally with a fatality rate near 93 percent. Early detection is rare, which is why a credible screen would be a big deal. MYNZ reported feasibility for PancAlert with 100 percent sensitivity and 95 percent specificity in early testing. It is early stage, but it uses the same mRNA plus analytics playbook the company applies in CRC.
CRC remains the core. ColoAlert is already used in Europe, now inside DoctorBox in Germany, and pooled next gen accuracy is quotable at \~92 percent CRC sensitivity, \~82 percent advanced adenomas, and \~95.8 percent high grade dysplasia. If the pancreas program advances with a blinded validation plan, a funded study timeline, and reuse of the ColoAlert workflow, the platform story gains real weight without heavy capex.
Do Your Own DD.

In shaky markets, recurring healthcare spend tends to hold. Preventive cancer screening is one of those lines. Colorectal cancer is roughly 1.9 million new cases and about 935,000 deaths per year worldwide. Five-year survival is near 90 percent when localized, but around 13 percent when distant. That math is why payers keep funding early detection even when risk assets wobble.
For MYNZ, the Europe-first story is tangible. ColoAlert is marketed via partner labs and now sits inside DoctorBox in Germany, an app with 1,000,000 plus registered users and 10M plus test results. Germany alone sees roughly 60,000 new CRC cases each year. Clinically, pooled next-gen performance is quotable: about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high-grade dysplasia. The decentralized kit model lets new labs come online without heavy capex.
Eyeing this sector, names like this can re-rate fast.

Colorectal cancer is huge and urgent. Roughly 1.9 million new cases and about 935,000 deaths worldwide each year. In the U.S., five year survival is near 90 percent when localized and about 13 percent when distant. Germany alone sees around 60,000 new cases per year. Early detection moves patients from late therapy to quick intervention.
For MYNZ, a single clean update can shift the multiple if it includes hard adoption data plus accuracy. ColoAlert’s pooled next gen read is roughly 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. Pair that with DoctorBox conversion, completed kits per week, median turnaround, and early reorders in Germany. Add a dated U.S. feasibility read and the path to a pivotal moves from talk to timeline.
If those metrics land together, investors can model real volume instead of headlines. If they do not, it remains a trading vehicle.
Do your own DD too

Big buyers just told the market where growth sits: cancer screening and precision diagnostics. Abbott agreeing to acquire Exact Sciences is not about one brand. It is a statement that early detection is strategic, scalable, and worth paying up for. If that is true for the giants, it sets a supportive backdrop for smaller platforms that already have product in use.
That is why I keep MYNZ on screen. ColoAlert is live in Europe through partner labs, with German distribution now boosted by DoctorBox. Clinically, pooled next gen reads are strong: roughly 92% CRC sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia. The business model is kits plus partner labs, so volume can scale without heavy capex. What I want next: DoctorBox conversion and completions, early reorders by region, and a firm U.S. feasibility date that moves the FDA path from talk to timeline.